PATHOLOGY & ONCOLOGY RESEARCHVol. 8 No. 1, 2002

 Article

Results of Ovary Tumor Treatment With Abdominally Administered 198Au Evaluated on the Basis of Long Term Follow Up

Mihály PATYÁNIK, Árpád MAYER, István POLGÁR

Uzsoki Hospital, Budapest, Hungary

 

In the period between 1959 and 1980 165 patients – previously operated with ovarian tumor – were treated by intraperitoneally administered 198Au in the Oncoradiological Centre of the Uzsoki Hospital. The stage distribution of the 158 patients with common epithelial histology was as it follows: Stage I/A 31; Stage I/B 9; Stage I/C 59; Stage II/A 19; Stage II/B 11; Stage II/C 7, Stage III/A 22. The five year survival result is the next: Stage I/A 90%; Stage I/B 78%; Stage I/C 58%; Stage II/A 26%; Stage II/B 27%; Stage II/C 14%; Stage III/A 18%. From the other 7 patients six had sex cord tumor and one lipid cell tumor. The number of the side effects is in good agreement with the data in literature. The use of 198Au for intraperitoneal treatment of ovary tumors is not contemporary today because of gamma radiation of radiogold, but intraperitoneal radiation treatment should not be forgotten. Pathology & Oncology Research, Vol 8, Nr 1, 54-57, 2002

Key words: ovary tumor; intraperitoneal therapy; radionuclide therapy


Received: Dec 17, 2001; accepted: Feb 24, 2002
Correspondence: Mihály PATYÁNIK, Uzsoki Hospital, Uzsoki utca 29 Budapest 1145, Hungary; Tel: +36-1-2517333/1206, Fax: +36-1-2511478

Click here to get the full-text version in PDF!
ad